Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioxyne Limited ( (AU:BXN) ) just unveiled an announcement.
Bioxyne Limited has announced its upcoming Annual General Meeting scheduled for November 26, 2025, in Sydney. Shareholders are encouraged to lodge proxy forms and submit questions in advance. This meeting is significant for stakeholders as it reflects the company’s commitment to transparency and shareholder engagement, potentially impacting its strategic direction and market positioning.
More about Bioxyne Limited
Bioxyne Limited is an Australian-headquartered international consumer health and pharmaceutical company, focusing on clinically effective health and wellness products, psychotropic and investigational medicines. Its wholly owned subsidiary, Breathe Life Sciences, is a GMP-licensed manufacturer and exporter of controlled substances, including medicinal cannabis, Psilocybin, and MDMA. The company operates globally with facilities in Australia, Japan, the UK, and Czechia, and is a market leader in manufacturing therapeutic goods.
Average Trading Volume: 4,309,804
Technical Sentiment Signal: Buy
Current Market Cap: A$91.22M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.